About SINO BIOPHARM Company

Sino Biopharm Co., Ltd. (“the Company” or “Sino Biopharm”) and its subsidiaries (“the Group”) are a leading, innovation-driven pharmaceutical group in China, with operations spanning the entire pharmaceutical value chain—from R&D platforms and intelligent manufacturing to a robust sales network. Our product portfolio includes a wide range of biologics and chemical drugs, placing us in a strong position across four major therapeutic areas: oncology, liver diseases, respiratory disorders, and surgery/anesthesia. The Company was listed on the Hong Kong Stock Exchange in 2000 and was included in the MSCI Global Standard Index’s China Index in 2013. In 2018, it was added to the Hang Seng Index; in 2019, it was included in the Hang Seng China Enterprises Index; and in 2020, it was named to both the Hang Seng Stock Connect Biotech 50 Index and the Hang Seng China (Hong Kong Listed) 25 Index. For five consecutive years, Sino Biopharm has been ranked among the “Top 50 Global Pharmaceutical Companies” published by the prestigious U.S. magazine “Pharmaceutical Executive,” and for three consecutive years, it has been recognized by Forbes (Asia) as one of the “Top 50 Best Companies in Asia-Pacific.” Sino Biopharm’s subsidiaries are located in Beijing, Shanghai, Nanjing, Lianyungang, and other cities, and the company operates multiple pharmaceutical production bases. Since its establishment, the Company has consistently achieved remarkable accomplishments and maintained steady growth. Its core subsidiaries, Zhengda Tianqing Pharmaceutical Group Co., Ltd. and Beijing Taidex Pharmaceutical Co., Ltd., have both been ranked among the top 100 Chinese pharmaceutical companies for many years. Building on a solid foundation of generic drug development, the Company is undergoing a comprehensive transformation toward innovation, with innovative drugs driving growth and their share of revenue steadily increasing year after year. Our internally developed pipeline is fueling this innovative shift and continuously enhancing our technological platforms. Under the leadership of a world-class scientific team, we are actively promoting internationalization and seizing opportunities in cutting-edge global markets. Sino Biopharm remains committed to its mission of “Healthcare Technology, Bringing Warmth to More Lives.” We are dedicated to innovation and patient care, striving to become a globally leading pharmaceutical enterprise. We look forward to sharing the fruits of development in the pharmaceutical and healthcare industries with like-minded partners, working together in solidarity for a prosperous future! The Group’s key subsidiaries include Zhengda Tianqing Pharmaceutical Group Co., Ltd. (“Zhengda Tianqing”), Beijing Taidex Pharmaceutical Co., Ltd. (“Beijing Taidex”), Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. (“Nanjing Zhengda Tianqing”), Jiangsu Zhengda Fenghai Pharmaceutical Co., Ltd. (“Jiangsu Zhengda Fenghai”), Jiangsu Zhengda Qingjiang Pharmaceutical Co., Ltd. (“Jiangsu Zhengda Qingjiang”), and invoX Pharma Limited (“invoX”). Nanjing Zhengda Tianqing, Jiangsu Zhengda Qingjiang, and Jiangsu Zhengda Fenghai have respectively been recognized by the Jiangsu Provincial Department of Science and Technology as the “Jiangsu Provincial Engineering Research Center for Anti-Tumor and Cardiovascular & Cerebrovascular Phytochemical Drug Preparations,” the “Engineering Research Center for Orthopedic Drug Preparations,” and the “Engineering Research Center for Parenteral Nutrition.” Zhengda Tianqing’s R&D center has been designated as a “Postdoctoral Research Station” by China’s Ministry of Human Resources and Social Security, and it is the only “New Hepatitis Drug Engineering Technology Research Center” in China. In December 2012, Beijing Taidex once again obtained GMP certification from Japan’s Ministry of Health, Labour and Welfare for foreign pharmaceutical companies. Japanese pharmaceutical firms can now entrust Beijing Taidex with the production and export to Japan of sterile preparations of pharmaceuticals currently under development or already marketed in Japan.